Prostate-specific antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
Objectives: Abiraterone Acetate (AA) is an important agent in the treatment of advanced prostate cancer. It was primarily approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) after failure of androgen deprivation therapy. There is still no avail-able strong data reg...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-02-01
|
| Series: | Archivio Italiano di Urologia e Andrologia |
| Subjects: | |
| Online Access: | https://www.pagepressjournals.org/index.php/aiua/article/view/11052 |